{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Acteoside", "Hepatocellular carcinoma", "Kallikrein", "Sorafenib", "Xenograft", "p53"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32993568", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "14"}, "DateRevised": {"Year": "2021", "Month": "04", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "09", "Day": "29"}], "Language": ["eng"], "ELocationID": ["936", "10.1186/s12885-020-07447-3"], "Journal": {"ISSN": "1471-2407", "JournalIssue": {"Volume": "20", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Sep", "Day": "29"}}, "Title": "BMC cancer", "ISOAbbreviation": "BMC Cancer"}, "ArticleTitle": "Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.", "Pagination": {"StartPage": "936", "MedlinePgn": "936"}, "Abstract": {"AbstractText": ["Hepatocellular carcinoma (HCC) is a common malignant tumor with characteristics of poor prognosis, high morbidity and mortality worldwide. In particular, only a few systemic treatment options are available for advanced HCC patients, and include sorafenib and the recently described atezolizumab plus bevacizumab regimen as possible first-line treatments. We here propose acteoside, a phenylethanoid glycoside widely distributed in many medicinal plants as a potential candidate against advanced HCC.", "Cell proliferation, colony formation and migration were analyzed in the three human HCC cell lines BEL7404, HLF and JHH-7. Angiogenesis assay was performed using HUVESs. The BEL7404 or JHH-7 xenograft nude mice model was established to analyze the possible antitumor effects of acteoside. qRT-PCR and western blotting were used to reveal the potential antitumor mechanisms of acteoside.", "Acteoside inhibited cell proliferation, colony formation and migration in all the three human HCC cell lines BEL7404, HLF and JHH-7. The prohibition of angiogenesis by acteoside was revealed by the inhibition of tube formation and cell migration of HUVECs. The combination of acteoside and sorafenib produced stronger inhibition of cell colony formation and migration of the HCC cells as well as of angiogenesis of HUVECs. The in vivo antitumor efficacy of acteoside was further demonstrated in BEL7404 or JHH-7 xenograft nude mice model, with an enhancement when combined with sorafenib in inhibiting the growth of JHH-7 xenograft. Further treatment of JHH-7 cells with acteoside revealed an increase in the level of tumor suppressor protein p53 as well as a decrease of kallikrein-related peptidase (KLK1, 2, 4, 9 and 10) gene level with no significant changes of the rest of KLK1-15 genes.", "Acteoside exerts an antitumor effect possibly through its up-regulation of p53 levels as well as inhibition of KLK expression and angiogenesis. Acteoside could be useful as an adjunct in the treatment of advanced HCC in the clinic."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China."}], "LastName": "Ma", "ForeName": "Di", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "China State Key Laboratory of New Drug & Pharmaceutical Process, Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, 1111 Rd. Zhongshanbeiyi, Hongkou, Shanghai, 200437, China."}], "LastName": "Wang", "ForeName": "Juan", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "China State Key Laboratory of New Drug & Pharmaceutical Process, Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, 1111 Rd. Zhongshanbeiyi, Hongkou, Shanghai, 200437, China."}], "LastName": "Liu", "ForeName": "Lu", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "China State Key Laboratory of New Drug & Pharmaceutical Process, Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, 1111 Rd. Zhongshanbeiyi, Hongkou, Shanghai, 200437, China."}], "LastName": "Chen", "ForeName": "Meiqi", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "China State Key Laboratory of New Drug & Pharmaceutical Process, Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, 1111 Rd. Zhongshanbeiyi, Hongkou, Shanghai, 200437, China. wangzhiyong108@126.com."}], "LastName": "Wang", "ForeName": "Zhiyong", "Initials": "Z"}], "GrantList": [{"GrantID": "18DZ2290900", "Agency": "Shanghai Science and Technology Committee", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Cancer", "NlmUniqueID": "100967800", "ISSNLinking": "1471-2407"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Glucosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Phenols"}, {"RegistryNumber": "0", "NameOfSubstance": "TP53 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Protein p53"}, {"RegistryNumber": "3TGX09BD5B", "NameOfSubstance": "acteoside"}, {"RegistryNumber": "9ZOQ3TZI87", "NameOfSubstance": "Sorafenib"}, {"RegistryNumber": "EC 3.4.21.-", "NameOfSubstance": "KLK5 protein, human"}, {"RegistryNumber": "EC 3.4.21.-", "NameOfSubstance": "Kallikreins"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug therapy", "genetics", "pathology"], "DescriptorName": "Carcinoma, Hepatocellular"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Movement"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Glucosides"}, {"QualifierName": [], "DescriptorName": "Hep G2 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects"], "DescriptorName": "Kallikreins"}, {"QualifierName": ["drug therapy", "genetics", "pathology"], "DescriptorName": "Liver Neoplasms"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["drug therapy", "genetics", "pathology"], "DescriptorName": "Neovascularization, Pathologic"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Phenols"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Sorafenib"}, {"QualifierName": ["genetics"], "DescriptorName": "Tumor Suppressor Protein p53"}, {"QualifierName": [], "DescriptorName": "Xenograft Model Antitumor Assays"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi: 10.1038/nrdp.2016.18.", "ArticleIdList": ["10.1038/nrdp.2016.18", "27158749"]}, {"Citation": "Sim HW, Knox J. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer. 2018;42(1):40\u201348. doi: 10.1016/j.currproblcancer.2017.10.007.", "ArticleIdList": ["10.1016/j.currproblcancer.2017.10.007", "29150141"]}, {"Citation": "Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: mechanisms of progression and immunotherapy. World J Gastroenterol. 2019;25(25):3151\u20133167. doi: 10.3748/wjg.v25.i25.3151.", "ArticleIdList": ["10.3748/wjg.v25.i25.3151", "PMC6626719", "31333308"]}, {"Citation": "Forner A, Da Fonseca LG, Diaz-Gonzalez A, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep. 2019;1(1):17\u201329. doi: 10.1016/j.jhepr.2019.02.003.", "ArticleIdList": ["10.1016/j.jhepr.2019.02.003", "PMC7001551", "32039350"]}, {"Citation": "Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153\u2013159. doi: 10.1053/j.semdp.2016.12.011.", "ArticleIdList": ["10.1053/j.semdp.2016.12.011", "28108047"]}, {"Citation": "Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u20131905. doi: 10.1056/NEJMoa1915745.", "ArticleIdList": ["10.1056/NEJMoa1915745", "32402160"]}, {"Citation": "He ZD, Ueda S, Akaji M, Fujita T, Inoue K, Yang CR. Monoterpenoid and phenylethanoid glycosides from Ligustrum pedunculare. Phytochemistry. 1994;36(3):709\u2013716. doi: 10.1016/S0031-9422(00)89802-7.", "ArticleIdList": ["10.1016/S0031-9422(00)89802-7", "7765002"]}, {"Citation": "Li H, Chou GX, Wang ZT, Hu ZB. HPLC determination of acteoside in Radix Rehmanniae. Zhongguo Zhong Yao Za Zhi. 2006;31(10):822\u2013824.", "ArticleIdList": ["17048666"]}, {"Citation": "Wong IY, He ZD, Huang Y, Chen ZY. Antioxidative activities of phenylethanoid glycosides from Ligustrum purpurascens. J Agric Food Chem. 2001;49(6):3113\u20133119. doi: 10.1021/jf0100604.", "ArticleIdList": ["10.1021/jf0100604", "11410017"]}, {"Citation": "Mulani SK, Guh JH, Mong KK. A general synthetic strategy and the anti-proliferation properties on prostate cancer cell lines for natural phenylethanoid glycosides. Org Biomol Chem. 2014;12(18):2926\u20132937. doi: 10.1039/c3ob42503g.", "ArticleIdList": ["10.1039/c3ob42503g", "24691797"]}, {"Citation": "Cheimonidi C, Samara P, Polychronopoulos P, Tsakiri EN, Nikou T, Myrianthopoulos V, Sakellaropoulos T, Zoumpourlis V, Mikros E, Papassideri I, et al. Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. Redox Biol. 2018;16:169\u2013178. doi: 10.1016/j.redox.2018.02.015.", "ArticleIdList": ["10.1016/j.redox.2018.02.015", "PMC5952579", "29505920"]}, {"Citation": "Attia YM, El-Kersh DM, Wagdy HA, Elmazar MM. Verbascoside: identification, quantification, and potential sensitization of colorectal Cancer cells to 5-FU by targeting PI3K/AKT pathway. Sci Rep. 2018;8(1):16939. doi: 10.1038/s41598-018-35083-2.", "ArticleIdList": ["10.1038/s41598-018-35083-2", "PMC6240071", "30446678"]}, {"Citation": "Liu S, Zhao Z, Huo Z, Xu Z, Zhong Y, Wang X, Yang Y, Wang Z. Osmanthus fragrans flower aqueous extract and its enriched acteoside inhibit melanogenesis and ultraviolet-induced pigmentation. Nat Prod Commun. 2018;13(5):575\u2013580."}, {"Citation": "Wang J, Ma S, Chen X, Zhang S, Wang Z, Mei Q. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. Investig New Drugs. 2019;37(5):828\u2013836. doi: 10.1007/s10637-018-0698-2.", "ArticleIdList": ["10.1007/s10637-018-0698-2", "30456603"]}, {"Citation": "Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54(10):1600\u20131607. doi: 10.1373/clinchem.2008.105189.", "ArticleIdList": ["10.1373/clinchem.2008.105189", "18687738"]}, {"Citation": "Tailor PD, Kodeboyina SK, Bai S, Patel N, Sharma S, Ratnani A, Copland JA, She JX, Sharma A. Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. Oncotarget. 2018;9(25):17876\u201317888. doi: 10.18632/oncotarget.24947.", "ArticleIdList": ["10.18632/oncotarget.24947", "PMC5915161", "29707153"]}, {"Citation": "Kontos CK, Mavridis K, Talieri M, Scorilas A. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects. Thromb Haemost. 2013;110(3):450\u2013457. doi: 10.1160/TH12-11-0791.", "ArticleIdList": ["10.1160/TH12-11-0791", "23446315"]}, {"Citation": "Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334. doi: 10.1016/S1470-2045(08)70285-7.", "ArticleIdList": ["10.1016/S1470-2045(08)70285-7", "19095497"]}, {"Citation": "Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u2013390. doi: 10.1056/NEJMoa0708857.", "ArticleIdList": ["10.1056/NEJMoa0708857", "18650514"]}, {"Citation": "Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3843\u20133849. doi: 10.3748/wjg.v21.i13.3843.", "ArticleIdList": ["10.3748/wjg.v21.i13.3843", "PMC4385530", "25852268"]}, {"Citation": "Liao YF, Rao YK, Tzeng YM. Aqueous extract of Anisomeles indica and its purified compound exerts anti-metastatic activity through inhibition of NF-kappaB/AP-1-dependent MMP-9 activation in human breast cancer MCF-7 cells. Food Chem Toxicol. 2012;50(8):2930\u20132936. doi: 10.1016/j.fct.2012.05.033.", "ArticleIdList": ["10.1016/j.fct.2012.05.033", "22634262"]}, {"Citation": "Zhang Y, Yuan Y, Wu H, Xie Z, Wu Y, Song X, Wang J, Shu W, Xu J, Liu B, et al. Effect of verbascoside on apoptosis and metastasis in human oral squamous cell carcinoma. Int J Cancer. 2018;143(4):980\u2013991. doi: 10.1002/ijc.31378.", "ArticleIdList": ["10.1002/ijc.31378", "29536537"]}, {"Citation": "Hwang TW, Kim DH, Kim DB, Jang TW, Kim GH, Moon M, Yoon KA, Choi DE, Park JH, Kim JJ. Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy. Int J Mol Med. 2019;43(3):1478\u20131486.", "ArticleIdList": ["30664150"]}, {"Citation": "Peerzada KJ, Faridi AH, Sharma L, Bhardwaj SC, Satti NK, Shashi B, Tasduq SA. Acteoside-mediates chemoprevention of experimental liver carcinogenesis through STAT-3 regulated oxidative stress and apoptosis. Environ Toxicol. 2016;31(7):782\u2013798. doi: 10.1002/tox.22089.", "ArticleIdList": ["10.1002/tox.22089", "26990576"]}, {"Citation": "Cui Q, Pan Y, Zhang W, Zhang Y, Ren S, Wang D, Wang Z, Liu X, Xiao W. Metabolites of dietary Acteoside: profiles, isolation, identification, and Hepatoprotective capacities. J Agric Food Chem. 2018;66(11):2660\u20132668. doi: 10.1021/acs.jafc.7b04650.", "ArticleIdList": ["10.1021/acs.jafc.7b04650", "29478321"]}, {"Citation": "Xiong Q, Hase K, Tezuka Y, Namba T, Kadota S. Acteoside inhibits apoptosis in D-galactosamine and lipopolysaccharide-induced liver injury. Life Sci. 1999;65(4):421\u2013430. doi: 10.1016/S0024-3205(99)00263-5.", "ArticleIdList": ["10.1016/S0024-3205(99)00263-5", "10421428"]}, {"Citation": "Zhao J, Liu T, Ma L, Yan M, Zhao Y, Gu Z, Huang Y. Protective effect of acteoside on immunological liver injury induced by Bacillus Calmette-Guerin plus lipopolysaccharide. Planta Med. 2009;75(14):1463\u20131469. doi: 10.1055/s-0029-1185796.", "ArticleIdList": ["10.1055/s-0029-1185796", "19548187"]}, {"Citation": "Lu B, Li M, Zhou F, Huang W, Jiang Y, Mao S, Zhao Y, Lou T. The Osmanthus fragrans flower phenylethanoid glycoside-rich extract: acute and subchronic toxicity studies. J Ethnopharmacol. 2016;187:205\u2013212. doi: 10.1016/j.jep.2016.04.049.", "ArticleIdList": ["10.1016/j.jep.2016.04.049", "27130643"]}, {"Citation": "Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem. 2002;48(8):1198\u20131205. doi: 10.1093/clinchem/48.8.1198.", "ArticleIdList": ["10.1093/clinchem/48.8.1198", "12142373"]}, {"Citation": "Sawant S, Snyman C, Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol. 2001;1(12):2063\u201380.", "ArticleIdList": ["11710536"]}, {"Citation": "Lu L, Yang Z, Zhu B, Fang S, Yang X, Cai W, Li C, Ma JX, Gao G. Kallikreinbinding protein suppresses growth of hepatocellular carcinoma by antiangiogenic activity. Cancer Lett. 2007;257(1):97\u2013106.", "ArticleIdList": ["17714861"]}, {"Citation": "Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res. 2010;30(9):3557\u201364.", "ArticleIdList": ["20944137"]}, {"Citation": "Zhou L, Feng Y, Jin Y, Liu X, Sui H, Chai N, Chen X, Liu N, Ji Q, Wang Y, Li Q. Verbascoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer. BMC Cancer. 2014;14:747.", "ArticleIdList": ["PMC4197337", "25282590"]}, {"Citation": "Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851\u20138.", "ArticleIdList": ["17178882"]}]}], "History": [{"Year": "2020", "Month": "3", "Day": "4"}, {"Year": "2020", "Month": "9", "Day": "21"}, {"Year": "2020", "Month": "9", "Day": "30", "Hour": "5", "Minute": "46"}, {"Year": "2020", "Month": "10", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "9", "Day": "29"}], "PublicationStatus": "epublish", "ArticleIdList": ["32993568", "PMC7526186", "10.1186/s12885-020-07447-3", "10.1186/s12885-020-07447-3"]}}]}